AstraZeneca heart drug in regulatory fast lane for wider use

April 29, 2015 7:04 AM

20 0

LONDON (Reuters) - U.S. regulators are to fast-track the review of a new use of AstraZeneca's heart drug Brilinta, meaning it could get the green light in the third quarter to be given to patients with a history of heart attacks.

The drugmaker said on Wednesday the decision by the Food and Drug Administration (FDA) reflected the potential of Brilinta to address an unmet medical need by reducing risks for patients who had a heart attack one to three years previously.

Also read: After law change, Greek medicinal users hope to enter cannabis business

Read more

To category page